CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Abdul Malik Setiawan, M.D, M.Infect.Dis.
School of Medicine, Faculty of Medicine and Health Sciences. State Islamic University Maulana Malik Ibrahim Malang
1.1 Introduction to COPD
Chronic Obstructive Pulmonary Disease (COPD) is a respiratory disease of major public health concern. The World Health Organization (WHO) estimates COPD will become the third leading cause of death worldwide by 2030 [1, 2]. A large cohort study performed in 2006 by The Burden of Obstructive Lung Disease (BOLD) Collaborative Research Group showed that the estimated prevalence of COPD in 12 major cities around the world was 10.1 % on average (Table 1.1) . In 2011, there were 139,598 deaths worldwide, due to COPD and it accounted for 5.5 % of total deaths [4, 5]. In Australia, in 2011, COPD caused 5,767 deaths among people aged 55 and over .
Cigarette smoking is the major risk factor for COPD . However, according to several studies, only 20-25% of smokers will develop COPD. Furthermore, amongst who have COPD, 20-23% have never smoked cigarettes before . In addition, the progression of COPD and airway inflammation persists despite smoking cessation .
Other risk factors that contribute to the development of COPD in non-smoking patients include biomass smoke, occupational exposure to dust and gasses, genetic factors such as α-1 antitrypsin deficiency and chronic respiratory disease such as asthma and tuberculosis [10-12]. Those factors are considered to cause chronic inflammation in the lungs, characterized by excessive production of inflammatory mediators. .
Table 1.1 Estimated prevalence of COPD according to GOLD staging in 12 cities around the world in 2006
City (Country) Number of respondents Number of eligible samples Estimated prevalence according to GOLD stage
No airflow obstruction Stage I Stage
II Stage III-IV
Guangzhou (China) 602 473 88.6% 4.2% 5.5% 1.7%
Adana (Turkey) 875 806 80.9% 8.6% 9.1% 1.5%
Salzburg (Austria) 1349 1258 73.9% 15.5% 9.2% 1.4%
Cape Town (South Africa) 896 847 76.2% 4.7% 12.4% 6.7%
Reykjavik (Iceland) 758 755 82.1% 8.9% 7.0% 1.9%
Hannover (Germany) 713 683 86.7% 7.3% 5.1% 0.8%
Krakow (Poland) 603 526 77.9% 11.2% 9.0% 1.9%
Bergen (Norway) 707 658 81.2% 10.5% 7.1% 1.2%
Vancouver (Canada) 856 827 80.7% 11.1% 7.3% 0.9%
Lexington (USA) 563 508 80.4% 5.3% 10.1% 4.2%
Manila (Philippines) 918 893 86.2% 1.4% 7.5% 5.0%
Sydney (Australia) 585 541 80.8% 8.4% 9.4% 1.4%
Estimated prevalence of patient with airflow obstruction according to global initiative for obstructive lung diseases (GOLD) criteria in 12 major cities presented by The Burden of Obstructive Lung Disease (BOLD) Collaborative Research Group (Buist et al. 2007).
1.2 Clinical Aspects of COPD
1.2.1 Definition, Diagnosis and Classification of COPD
According to the global initiative for obstructive lung disease (GOLD), COPD is defined as a preventable and treatable disease characterized by progressive and irreversible airflow limitation with abnormal inflammatory responses of the lungs . Emphysema and bronchitis can cause chronic airflow limitation, thus increasing the long-term risk for developing COPD [15, 16].
Figure 1.1 Illustrated image of patient taking spirometry test
A diagnosis of COPD can be made by assessing clinical symptoms, medical history, physical examination and spirometry. Patients with COPD generally present with chronic and progressive dyspnoea, cough and sputum production. A patient with suspected COPD will undergo spirometry testing after taking either a bronchodilator or a corticosteroid medication as illustrated in figure 1.1.
A post-bronchodilator ratio between Forced Expiration Volume in 1 second (FEV1) and Forced Vital Capacity (FVC) of less than 70 % is a positive finding for COPD. In addition to the FEV1/FVC ratio, the predicted FEV1 (%) is used to classify COPD patients according to their severity of disease. Predicted FEV1 is the ratio between a patient’s FEV1 and the average FEV1% in the population for any person of a similar age, sex and body composition. GOLD classified four stages of COPD and severity based on the predicted FEV1 (Table 1.2).
Table 1.2 Severity classification of COPD based on the level of airflow limitation
Classification FEV1 Predicted (%) Severity
GOLD 1 FEV1 ≥ 80% predicted Mild
GOLD 2 50% ≤ FEV1 < 80 % predicted Moderate
GOLD 3 30 % ≤ FEV1 < 50 % predicted Severe
GOLD 4 FEV1 < 30 % predicted Very severe
1.2.2 Pathogenesis of COPD
Long term exposure to noxious substances, such as cigarette and biomass smoke, induces chronic inflammation in COPD patients. This is characterized by an increase of cytokine production by inflammatory cells which leads to excessive mucus production and alveolar sac destruction . While the presence of excessive mucus decreases the diameter of the airway, the pathological changes to the alveolar sacs causes the lungs to lose their ability to recoil for expiration . In combination, the reduced airway diameter and the reduced ability to recoil results in the abnormal retention of air (air trapping) in the lungs, especially during expiration . Figure 1.2 illustrates the pathological changes in COPD lungs.
Although noxious substances are considered to be the leading cause of chronic inflammation in COPD, acute and chronic respiratory infections may also maintain the inflammatory environment in the lung parenchyma even in the absence of noxious substances. For example, pathogen colonisation of the lower respiratory airway can cause airway epithelial injury and chronic mucus secretion which perpetuates the chronic inflammation . Moreover, respiratory infections are a frequent triggers of COPD exacerbations .
Figure 1.2 Illustrated image of pathological changes in lungs of COPD patients
The location of the lungs and airways in the body. The inset image shows a detailed cross-section of the bronchioles and alveoli. (B) Damaged lungs in COPD. The inset image shows a detailed cross-section of the damaged bronchioles and alveolar walls.
1.2.3 Acute Exacerbation of COPD (AECOPD)
Acute exacerbation of COPD (AECOPD) is a condition where COPD-related symptoms, such as dyspnoea and productive cough, suddenly become worse relative to the baseline symptoms. There are estimated three to five exacerbation events per year in patients with COPD, with an average recovery time (to baseline symptoms) of 35 days per exacerbation. However, in some patients, a second exacerbation event occurs before recovery from the first resulting in progressively worse symptoms . Frequent exacerbations contributes to a long term decline in both lung function and patient’s quality of life . Therefore, a preventive management of acute exacerbation is very important for COPD patients.
1.3 Relationship between AECOPD and respiratory infection
AECOPD is highly associated with an increase of morbidity and mortality in patients with COPD. AECOPD is mostly caused by respiratory infections but also to some extent by air pollution. Respiratory infections in AECOPD can be bacterial, viral or bacterial and viral co-infection. Nevertheless, bacterial infection is considered as the predominant cause of AECOPD .
The three most common bacterial pathogens isolated from AECOPD patients are Haemophilus influenza, Moraxella catarrhalis and Streptococcus pneumoniae. Other bacterial pathogens which are less commonly isolated are Haemophilus parainfluenzae, Staphylococcus aureus, Pseudomonas aeruginosa and Enterobacteriaceae spp. Overall, 60% of AECOPD patients are colonised by bacterial pathogens, with non-typeable Haemophilus influaenzae (NTHI) counted as the most predominant agent .
In terms of viral infection, two meta-analyses performed by Mohan, Chandra  and Wu, Chen  showed that the weighted mean prevalence (WMP) of respiratory viral infection in AECOPD was between 34.1 and 39.3 %. The three most common viral agents were picornavirus/rhinovirus, influenza virus and respiratory syncytial virus (RSV). Given the significant number of viral infections in AECOPD, it would seem that the role of viral infection in AECOPD has been previously underestimated. Therefore, preventive strategies against microbial infections, either bacterial or viral, such as vaccination or antibody-based intervention become important.
1.4 New potential treatment strategies in AECOPD
Bronchodilator, antibiotic and corticosteroid medications are still the preferred drug of choice for treating acute exacerbation in COPD . A large cohort study performed by Stefan et al. showed that the use of antibiotics and systemic corticosteroids in AECOPD patients related to better short-term outcomes such as reduced inpatient mortality and 30 day readmission to hospital . However, excessive and long term usage of antibiotics can lead to antibiotic resistance. Furthermore, it is clearly understood that long-term usage of either inhaled or systemic corticosteroid will lead to many adverse effects such as hormone imbalance, osteoporosis, immune suppression, muscle weakness, posterior sub-capsular cataracts and many more .
Previous study has proposed the manipulation of CTLA-4 and PD-1 co-inhibitory receptors in COPD patients might leads to superior Th1 responses NTHI infection as recently shown in cancer and chronic viral infection [28-30]. A schematic diagram of monoclonal antibody blocking against CTLA-4 and PD-1 receptor is illustrated in Figure 1.3.
Figure 1.6 CTLA-4 and PD-1 modulate different aspects of the T-cell response. (A) CD28:B7 interaction activate T cells and increase their effector functions (e.g. production of IFNγ). CTLA-4 is upregulated upon T cell activation in lymphatic tissues, leading to decreased effector function (e.g. decreased IFNγ release). (B) PD-1 is highly expressed on T cells in peripheral tissues upon T cell activation. PD-1 ligation decreases T cell functions. (A, B) Monoclonal antibodies against CTLA-4 and PD-1 can restore T cell functions .
In conclusion, increasing Th1 responses in patients with COPD might lead to better protection against microorganisms responsible to respiratory infection. As respiratory infection is one of the most important factor for COPD patients to develop exacerbation, enhancing Th1 responses by blocking CTLA-4 and PD-1 co-inhibitory receptors promise new potential approach in preventing exacerbation in patients with COPD.
1. World Health Organization. Chronic obstructive pulmonary disease (COPD). 2011 [cited 2015 29 January]; Available from: http://www.who.int/respiratory/copd/en/.
2. World Health Organization. The top 10 causes of death. 2014 [cited 2015 29 January]; Available from: http://www.who.int/mediacentre/factsheets/fs310/en/.
3. Buist, A.S., et al., International variation in the prevalence of COPD (The BOLD Study): a population-based prevalence study. The Lancet, 2007. 370: p. 741-750.
4. Ford, E.S., et al., COPD Surveillance-United States, 1999-2011. CHEST, 2013. 144(1): p. 284-305.
5. Hoyert, D.L. and J. Xu, Deaths: Preliminary Data for 2011. National Vital Statistic Reports, 2012. 61(6): p. 1-51.
6. Australian Institute of Health and Welfare, et al., Mortality from asthma and COPD in Australia. 2014, AIHW: Canberra.
7. Mannino, D.M. and A.S. Buist, Global burden of COPD: risk factors, prevalence, and future trends. The Lancet, 2007. 370: p. 765-773.
8. Lamprecht, B., et al., COPD in never smokers. CHEST, 2011. 139: p. 752-763.
9. Lapperre, T.S., et al., Relation between duration of smooking cessation and bronchial inflamation in COPD. Thorax, 2006. 61: p. 115-121.
10. Salvi, S.S. and P.J. Barnes, Chronic obstructive pulmonary disease in non-smokers. The Lancet, 2009. 374: p. 733-743.
11. Viegi, G., et al., Definition, epidemiology and natural history of COPD. Eur Respir J, 2007. 30(5): p. 0903-1936.
12. Diaz-Guzman, E. and D.M. Mannino, Epidemiology and Prevalence of Chronic Obstructive Pulmonary Disease. Clin Chest Med, 2014. 35: p. 7-16.
13. Hillas, G., et al., Managing comorbidities in COPD. International Journal of Chronic Obstructive Pulmonary Disease, 2015. 10: p. 95-109.
14. Vestbo, J., et al., Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med., 2013. 187: p. 347-365.
15. Guerra, S., et al., Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax, 2009. 64: p. 894-900.
16. Nakano, Y., et al., Computed Tomographic Measurements of Airway Dimensions and Emphysema in Smokers. Am J Respir Crit Care Med., 2000. 162: p. 1102-1108.
17. O’Donnell, R., et al., Inflammatory cells in the airways in COPD. Thorax, 2006. 61: p. 448-454.
18. Sethi, S. and T.F. Murphy, Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clinical Microbiology reviews, 2001. 14(2): p. 336-363.
19. Wedzicha, J.A., et al., Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Medicine, 2013. 11(181): p. 1-10.
20. Seemungal, T.A.R., et al., Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med., 2000. 161(5): p. 1608-1613.
21. Donaldson, G.C., et al., Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002. 57: p. 847-852.
22. Finney, L.J., et al., Lower airway colonization and inflamatory response in COPD: a focus on Haemophilus influenzae. International Journal of COPD, 2014. 4(9): p. 1119-1132.
23. Mohan, A., et al., Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: A systematic review. Respirology, 2010. 15: p. 536-542.
24. Wu, X., et al., Prevalence and risk of viral infection in patients with acute exacerbation of chronic obstructive pulmonary disease: a meta-analysis. Mol Biol Rep, 2014. 41: p. 4743-4751.
25. Stefan, M.S., et al., Association between antibiotic treatment and outcomes in patients hospitalized with acute exacerbation of COPD treated with systemic steroids. CHEST, 2013. 143(1): p. 82-90.
26. McEvoy, C.E. and D.E. Niewoehner, Adverse effects of corticosteroid therapy for COPD: A critical review. CHEST, 1997. 111(3): p. 732-743.
27. Berenson, C.S., et al., Impaired Alveolar Macrophage Response to Haemophilus Antigens in Chronic Obstructive Lung Disease. Am J Respir Crit Care Med., 2006. 174: p. 31-40.
28. Tumeh, P.C., et al., PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 2014. 515(7528): p. 568-571.
29. Velu, V., et al., Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology, 2015. 12: p. 14.
30. Nakamoto, N., et al., Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade. PLoS Pathogens, 2009. 5(2): p. e1000313.
31. Hotchkiss, R.S. and S. Opal, Immunotherapy for sepsis – A new approach against an ancient foe. N Engl J Med, 2010. 363(1): p. 87-89.
32. Ott, P.A., F.S. Hodi, and C. Robert, CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res, 2013. 19(19): p. 5300-9.